Amer Zeidan: Can Early Blood Count Changes Predict Imetelstat Response in Lower Risk MDS?
Amer Zeidan, Chief, Division of Hematologic Malignancies; Professor of Medicine at Yale University, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Blood Cancer Journal, adding:
“Our newest paper on association between early neutropenia and thrombocytopenia with subsequent clinical response to imetelstat in lower risk MDS.”
Title: Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes
Authors: Amer M. Zeidan, Valeria Santini, María Díez-Campelo, Michael R. Savona, Mikkael A. Sekeres, Yazan F. Madanat, Pierre Fenaux, Azra Raza, Moshe Mittelman, Sylvain Thépot, Rena Buckstein, Ulrich Germing, David Valcárcel, Anna Jonášová, Sheetal Shah, Qi Xia, Libo Sun, Shyamala Navada, Tymara Berry, Uwe Platzbecker and Rami S. Komrokji
Stay updated on all scientific advances Hemostasis Today.
-
Sep 4, 2026, 12:02Khalid Abdelsamea Mohamedahmed: Routine Blood Parameters in Pediatric Sickle Cell Anemia
-
Sep 4, 2026, 11:37Consuela A. Albright: The Power of Community Advocacy in Sickle Cell Disease
-
Sep 4, 2026, 11:18Aanika Roshni: When Blood, Biology, and Mechanics Intersect
-
Sep 4, 2026, 10:01Ifeanyichukwu Ifechidere: Making Coagulation Simpler and More Practical
-
Sep 4, 2026, 09:49Omid Khalafi: When the ‘Rules of Three’ Break – What Is Really Happening?
-
Sep 4, 2026, 09:27Hilly Paige: What ESC 2026 Taught Us About LDL-C Management
-
Sep 4, 2026, 05:38Faizan Khan: Why Common Exposures Matter in VTE Risk
-
Sep 4, 2026, 04:56Marwa Mostafa: Microcytosis Is Not Always Iron Deficiency
-
Sep 4, 2026, 03:18Mukesh Kumar Maurya: Beyond ‘aPL Thrombosis’ – A Modern Approach to APS